Vestal Point Capital LP Increases Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Vestal Point Capital LP boosted its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 67.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 710,000 shares of the company's stock after acquiring an additional 285,000 shares during the quarter. Vestal Point Capital LP owned 1.30% of Bicara Therapeutics worth $12,368,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Spire Wealth Management bought a new position in Bicara Therapeutics in the 4th quarter valued at about $31,000. BNP Paribas Financial Markets bought a new position in Bicara Therapeutics in the 4th quarter valued at about $32,000. Legal & General Group Plc bought a new position in Bicara Therapeutics in the 4th quarter valued at about $33,000. Summit Investment Advisors Inc. bought a new position in Bicara Therapeutics in the 4th quarter valued at about $35,000. Finally, Virtus ETF Advisers LLC bought a new position in Bicara Therapeutics in the 4th quarter valued at about $69,000.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BCAX shares. HC Wainwright dropped their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price on the stock in a research report on Friday. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $31.86.

Bicara Therapeutics Stock Down 40.8%

Shares of BCAX traded down $6.39 during mid-day trading on Friday, reaching $9.27. 7,204,269 shares of the stock traded hands, compared to its average volume of 532,519. The firm has a fifty day moving average price of $12.91 and a 200 day moving average price of $14.96. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.28). Equities research analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.